Get the Stockscreener App
30.97
0.93%
-0.29
After Hours:
31.05
0.08
+0.26%
Moderna Inc stock is traded at $30.97, with a volume of 5.75M.
It is down -0.93% in the last 24 hours and up +19.58% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$31.26
Open:
$31.525
24h Volume:
5.75M
Relative Volume:
0.55
Market Cap:
$11.98B
Revenue:
$3.14B
Net Income/Loss:
$-3.36B
P/E Ratio:
-3.5475
EPS:
-8.73
Net Cash Flow:
$-4.03B
1W Performance:
-5.78%
1M Performance:
+19.58%
6M Performance:
-13.71%
1Y Performance:
-74.43%
1-Day Range:
$30.88
$32.07
1-Week Range:
$30.88
$33.31
52-Week Range:
$23.15
$125.68
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
30.97 | 12.71B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
New York State Common Retirement Fund Sells 33,365 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
What drives Moderna Inc. stock pricePowerful growth strategies - Autocar Professional
Lexicography: Clear And Unequivocal - The National Law Review
Wealthfront Advisers LLC Increases Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
After Moderna Pulled Its Shot, Combination Flu/COVID Vaccines Hang in Limbo - BioSpace
What analysts say about Moderna Inc. stockFree Investment Timing Strategies - jammulinksnews.com
Moderna Bets Big On New Vaccines After Stock Tumbles - Finimize
Moderna, Inc. (NASDAQ:MRNA) Shares Sold by South Dakota Investment Council - MarketBeat
Is Moderna Inc. a good long term investmentRobust investment performance - jammulinksnews.com
Moderna Inc. Stock Analysis and ForecastMarket-beating returns - Jammu Links News
Edgestream Partners L.P. Has $2.78 Million Stock Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
OVERSEA CHINESE BANKING Corp Ltd Buys 17,268 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Shares Acquired by Nisa Investment Advisors LLC - MarketBeat
Moderna, Inc. (MRNA) Aktienkurs, Nachrichten, Kurs und Verlauf - yahoo.co
Here's Why Moderna (MRNA) Fell More Than Broader Market - Yahoo Finance
Moderna, Lantheus, Centene, AMN Healthcare Services, and NeoGenomics Shares Plummet, What You Need To Know - Yahoo Finance
How IBM and Moderna’s partnership could lead to an explosion in drug development - Fast Company
Investors Buy Large Volume of Call Options on Moderna (NASDAQ:MRNA) - MarketBeat
Moderna cancels plans to build Japan plant on poor business environment - Reuters
Moderna gets full FDA approval for kids COVID-19 vaccine - MSN
Moderna, Inc.'s (NASDAQ:MRNA) Price Is Right But Growth Is Lacking After Shares Rocket 26% - simplywall.st
Moderna cancels mRNA production plant in Japan (MRNA:NASDAQ) - Seeking Alpha
Cwm LLC Purchases 28,831 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Lobbying Update: $120,000 of MODERNA INC. lobbying was just disclosed - Quiver Quantitative
How IBM and Moderna (MRNA) Are Using Quantum Computing to Design Vaccines Faster - TipRanks
Moderna to Report Second Quarter 2025 Financial Results on Friday, August 1, 2025 - Amarillo Globe-News
Moderna Receives Full U.S. FDA Approval for COVID-19 Vaccine, Spikevax, in Children Aged 6 Months Through 11 Years at Increased Risk for COVID-19 Disease - Knoxville News Sentinel
IBM-Moderna Showcase Quantum-Enhanced Drug Discovery - HPCwire
IBM and Moderna Team Up on Quantum Study. What It Means for the World of Medicine. - Barron's
Director, Strategic Forecasting, Oncology job with Moderna, Inc. | 1402245670 - New Scientist
Moderna’s latest approval again reveals FDA rift over COVID vaccines - BioPharma Dive
William Blair Issues Negative Outlook for Moderna Earnings - MarketBeat
Bank of New York Mellon Corp Purchases 34,034 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
FDA Fully Approves Moderna’s COVID-19 Vaccine for Some Young Children - Vaccine Advisor
Lobbying Update: $100,000 of MODERNA US INC. lobbying was just disclosed - Quiver Quantitative
Moderna patent for mRNA vaccine knocked back, for now - Lawyerly
Moderna: Ready For The Redemption Arc (NASDAQ:MRNA) - Seeking Alpha
Reflecting On Therapeutics Stocks’ Q1 Earnings: Moderna (NASDAQ:MRNA) - Yahoo Finance
Opinion: It's Time to Load Up on This Biotech Giant After Its 80% Crash - Yahoo Finance
Opinion: It's Time to Load Up on This Biotech Giant After Its 80% Crash - The Motley Fool
What to Expect From Moderna's Next Quarterly Earnings Report - MSN
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.87%
0.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):